LONDON--(BUSINESS WIRE)--Sep 10, 2018--Technavio has announced their latest pipeline analysis report on the drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat laryngeal cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180910005814/en/
Technavio has published a new report on the drug development pipeline for the treatment of laryngeal cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Laryngeal cancer: Market overview
Laryngeal cancer, which is also known as larynx cancer, is a type of head and neck cancer where tumor cells are formed in the tissue of the larynx. The larynx is a part of the throat and is situated between tongue and trachea. It contains vocal cords, which are responsible for manipulation of pitch and volume of speech and are required for phonation. It is also known as the voice box.
According to a senior market research analyst at Technavio, “Larynx cancer is caused due to smoking, eating tobacco, and drinking excessive alcohol. It can also be caused due to human papillomavirus. Conditions such as poor diet, low immunity, and family history may also cause larynx cancer. Exposure to some chemicals such as formaldehyde, nickel, isopropyl alcohol, sulfuric acid mist, and diesel fumes can also lead to this disease. Moreover, regular exposure to high level of wood dust, coal dust, paint fumes, and coal as a fuel source can result in laryngeal cancer.”
Laryngeal cancer: Segmentation analysis
This pipeline analysis report segments the laryngeal cancer market based on therapies employed (monotherapy and combination therapy), RoA (oral), therapeutic modality (small molecule, monoclonal antibody, and biological), targets (EGFR, ETBR, HER2, immune system, PI3K, PARP, protein synthesis, tumor cells, and WEE1 kinase), MoA (EGFR inhibitor, ETBR antagonists, HER2 inhibitor, immunomodulator, PI3K inhibitor, PARP inhibitors, protein synthesis inhibitors, and WEE1 kinase inhibitor), geographical segmentation (US, UK, and The Netherlands) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 60% of the molecules that are being investigated for the treatment of laryngeal cancer are small molecules.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
Drugs under developmentIndications coverage
Drug Development Strategies
Therapies employedRoATherapeutic modalityGeographical coverage
Type of playersCompany overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180910005814/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA NETHERLANDS
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH ONCOLOGY PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/10/2018 02:11 PM/DISC: 09/10/2018 02:11 PM